Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (symbol: MIRM) is a biopharmaceutical company headquartered in Foster City, California. Established in 2018, the company focuses on the development and commercialization of innovative therapies aimed at treating debilitating liver diseases. Mirum Pharmaceuticals is dedicated to addressing rare and orphan diseases, making significant strides in this niche sector of the healthcare market.
At the core of Mirum Pharmaceuticals' product pipeline is Maralixibat, an investigational oral drug currently in phase 3 clinical trials. Maralixibat is being studied for its efficacy in treating several severe liver conditions, including Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), and Biliary Atresia. This product represents a potential breakthrough in providing therapeutic options for these challenging conditions.
In addition, the company has developed Volixibat, a drug aimed at treating Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Sclerosing Cholangitis (PSC). These ongoing projects highlight Mirum Pharmaceuticals' commitment to advancing the treatment landscape for liver diseases with significant unmet medical needs.
Mirum Pharmaceuticals has achieved notable milestones, such as the approval of Livmarli, an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor. Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS), providing much-needed relief for those affected by this condition.
The company stands out for its strategic approach to identifying, acquiring, and developing novel therapies. It has established partnerships and collaborations to bolster its research endeavors and expand its reach in the biopharmaceutical industry. With a robust pipeline and a clear focus on debilitating liver diseases, Mirum Pharmaceuticals continues to make significant progress in its mission to improve patient outcomes and quality of life.
For the latest news and updates about Mirum Pharmaceuticals, including recent achievements, ongoing projects, and financial performance, investors and stakeholders can rely on resources like StockTitan for comprehensive and timely information.
Stay informed about Mirum Pharmaceuticals, Inc. and its groundbreaking work in the biopharmaceutical sector, and keep track of the latest developments and stock performance on StockTitan.
Mirum Pharmaceuticals (NASDAQ: MIRM) showcased significant findings at the NASPGHAN Annual Meeting regarding maralixibat's long-term benefits for patients with Alagille syndrome (ALGS). Data presented highlighted a 70% reduction in clinical events over six years and substantial improvements in growth metrics over four years. Additionally, a multi-national analysis revealed significant caregiver impacts due to ALGS. The company continues to pursue further evaluations of maralixibat and plans a symposium on its clinical benefits.
Mirum Pharmaceuticals, Inc. (MIRM) announced that its Compensation Committee granted inducement awards to nine new employees on October 10, 2022. This includes non-qualified stock options to purchase 52,650 shares and 26,400 restricted stock units (RSUs) under Mirum’s 2020 Inducement Plan. The stock options have an exercise price of $18.22 and will vest over four years. RSUs will vest over three years. The awards are designed to incentivize employee retention and align their interests with shareholders.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will present three research posters and host a symposium at the NASPGHAN Annual Meeting in Orlando, Florida, from October 12-16, 2022. Key presentations include:
- Poster #290: Maralixibat improves growth in Alagille Syndrome patients.
- Poster #291: Improved event-free survival observed in maralixibat-treated patients.
- Poster #552: Caregiver burden analysis for Alagille Syndrome.
The symposium, “Beyond Itch,” will occur on October 13, featuring several distinguished speakers.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced on September 10-11, 2022, the granting of inducement awards to 11 new employees, comprising 47,750 stock options and 23,900 restricted stock units (RSUs). The stock options have an exercise price of $25.15, equal to the closing price on September 9, 2022, and will vest over four years. The RSUs will vest over three years. This award follows Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support the company's growth in treating rare diseases.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced its participation in key investor conferences, including Citi's 17th Annual BioPharma Conference on September 7, 2022, H.C. Wainwright's Global Investment Conference on September 12-13, 2022, and Baird's Global Healthcare Conference on September 14, 2022. The company focuses on rare and orphan diseases, notably with its approved treatment LIVMARLI® for Alagille syndrome. Mirum is also advancing its pipeline with investigational therapies targeting debilitating liver diseases, including ongoing clinical trials for pediatric and adult conditions.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has closed its underwritten public offering of 4,000,000 shares of common stock at $23.00 per share, raising gross proceeds of $92 million. The offering included full exercise of underwriters' options for an additional 521,739 shares. This was conducted under an effective shelf registration statement filed with the SEC. Mirum focuses on developing therapies for rare liver diseases, with its approved medication LIVMARLI® and investigational treatments for various liver conditions.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced on August 10, 2022 that it granted inducement awards of non-qualified stock options for 28,250 shares and 14,100 RSUs to eight new employees. Each stock option has an exercise price of $24.93 per share, the closing price on the grant date, and will vest over four years. The RSUs will vest over three years. These awards comply with Nasdaq Listing Rule 5635(c)(4) and are part of Mirum’s 2020 Inducement Plan. Mirum focuses on rare diseases, offering LIVMARLI for Alagille syndrome and has investigational treatments for other liver diseases.
Mirum Pharmaceuticals announced the pricing of its underwritten public offering, consisting of 3,478,261 shares at $23.00 each, aiming for gross proceeds of $80 million. Underwriters have a 30-day option to buy an additional 521,739 shares. The offering's closure is expected on August 12, 2022. J.P. Morgan, SVB Securities, and Evercore ISI are the joint managers for this offering, which is under a previously filed shelf registration statement. Mirum focuses on developing therapies for rare liver diseases, with products like LIVMARLI and ongoing clinical trials.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has initiated an underwritten public offering to raise
Mirum Pharmaceuticals reported a net product sales figure of $17.5 million for LIVMARLI in Q2 2022, bringing year-to-date sales to $28.4 million. While total operating expenses rose slightly to $48.9 million, R&D expenses decreased to $25.4 million. The company recorded a net loss of $26.9 million, a reduction from $43.9 million in Q2 2021. Anticipated milestones include EMA approval for Alagille syndrome and Phase 3 data for PFIC trials later this year. A conference call for further updates is scheduled for August 4, 2022.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
What is the focus of Mirum Pharmaceuticals, Inc.?
What is Maralixibat used for?
Where is Mirum Pharmaceuticals headquartered?
What is Livmarli?
When was Mirum Pharmaceuticals founded?
What is Volixibat being developed for?
What are the recent achievements of Mirum Pharmaceuticals?
How does Mirum Pharmaceuticals contribute to the biopharmaceutical industry?
How can I get the latest updates on Mirum Pharmaceuticals?
What products are in Mirum Pharmaceuticals' pipeline?
